Repositioning Candidate Details
| Candidate ID: | R1251 |
| Source ID: | DB09221 |
| Source Type: | experimental |
| Compound Type: | small molecule |
| Compound Name: | Polaprezinc |
| Synonyms: | beta-Alanyl-L-histidinato zinc; Polaprezinc; Zinc L-carnosine |
| Molecular Formula: | C9H12N4O3Zn |
| SMILES: | NCCC(=O)N1[Zn]OC(=O)[C@@H]1CC1=CN=CN1 |
| Structure: |
|
| DrugBank Description: | Polaprezinc is a chelated form of zinc and L-carnosine. It is a zinc-related medicine approved for the first time in Japan, which has been clinically used to treat gastric ulcers . It was determined that polaprezinc may be effective in pressure ulcer treatment . A study in 2013 showed that CO-administration of polaprezinc may be effective against small intestine mucosal injury associated with long-term aspirin therapy . |
| CAS Number: | 107667-60-7 |
| Molecular Weight: | 289.6 |
| DrugBank Indication: | Peptic ulcer disease, dyspepsia . |
| DrugBank Pharmacology: | Used to treat/manage peptic ulcer disease or irritation of the gastrointestinal tract by promoting tissue healing by the elimination of free radicals . |
| DrugBank MoA: | Polaprezinc increases the expression of various antioxidant enzymes, including superoxide dismutase 1 (SOD-1), SOD-2, heme oxygenase-1 (HO-1), glutathione S-transferase (GST), glutathione peroxidase (GSH-px), peroxidredoxin-1 (PRDX1; PRXI) and PRXD5 (PRXV). This process occurs in the gastric mucosa, defending mucosal cells against reactive oxygen species. This drug inhibits the activity of the transcription factor nuclear factor-kappaB (NF-kB) and decreases the expression of various inflammatory cytokines, including interleukin (IL) 1beta, IL-6, IL-8, and tumor necrosis factor alpha (TNF-a). Polaprezinc also promotes the expression of numerous growth factors, including as platelet-derived growth factor-B (PDGF-B), vascular endothelial growth factor (VEGF), and nerve growth factor (NGF), in addition to various heat shock proteins (HSPs), including HSP90, HSP70, HSP60, HSP47, HSP27, and HSP10. This process promotes tissue growth and protects against damage the gastric mucosa . |
| Targets: | Tumor necrosis factor inhibitor; Interleukin-6 inhibitor; Interleukin-3 inhibitor; Vascular endothelial growth factor receptor 1 agonist; Beta-nerve growth factor agonist; Platelet-derived growth factor receptor beta agonist; Heat shock protein HSP 90-alpha agonist; Heat shock protein HSP 90-beta agonist |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|